Siekierka JJ et al. |
Potential roles of other FK 506-binding proteins in mediating the effects of FK 506. |
1991 |
Transplant. Proc. |
pmid:1721256
|
Morris RE |
In vivo immunopharmacology of the macrolides FK 506 and rapamycin: toward the era of rational immunosuppressive drug discovery, development, and use. |
1991 |
Transplant. Proc. |
pmid:1721257
|
Kobayashi M et al. |
FK 506 assay past and present--characteristics of FK 506 ELISA. |
1991 |
Transplant. Proc. |
pmid:1721258
|
Warty VS et al. |
Practical aspects of FK 506 analysis (Pittsburgh experience). |
1991 |
Transplant. Proc. |
pmid:1721259
|
Blanc P et al. |
Antiproliferative effect of FK 506 and cyclosporine on adult human hepatocytes in culture. |
1991 |
Transplant. Proc. |
pmid:1721288
|
Loréal O et al. |
FK 506 is less cytotoxic than cyclosporine to human and rat hepatocytes in vitro. |
1991 |
Transplant. Proc. |
pmid:1721289
|
McCauley J et al. |
Cyclosporine and FK 506 induced inhibition of renal epithelial cell proliferation. |
1991 |
Transplant. Proc. |
pmid:1721290
|
McLachlan G et al. |
Growth inhibition of the MOLT-4 human T-leukemia cell line. A comparison of cyclosporine and FK 506. |
1991 |
Transplant. Proc. |
pmid:1721291
|
Woo J et al. |
Effects of FK 506, mycophenolic acid, and bredinin on OKT-3-, PMA-, and alloantigen-induced activation molecule expression on cultured CD4+ and CD8+ human lymphocytes. |
1991 |
Transplant. Proc. |
pmid:1721319
|
Chen-Woan M et al. |
Diminished lymphocyte growth from endomyocardial biopsies from cardiac transplant patients on FK 506 immunosuppression. |
1991 |
Transplant. Proc. |
pmid:1721320
|
Fukuzawa M et al. |
Effect of FK 506 on CD4+ and CD8+ T-cell function in vivo. |
1991 |
Transplant. Proc. |
pmid:1721321
|
Takaori K et al. |
Effects of FK 506 on in vivo immunity in comparison to cyclosporine. |
1991 |
Transplant. Proc. |
pmid:1721322
|
Jordan ML et al. |
Inhibition of T-cell function by FK 506 and cyclosporine is not accompanied by alterations in intracellular calcium. |
1991 |
Transplant. Proc. |
pmid:1721323
|
Green M et al. |
Infectious complications of pediatric liver transplantation under FK 506. |
1991 |
Transplant. Proc. |
pmid:1721352
|
Torre-Cisneros J et al. |
The spectrum of aspergillosis in liver transplant patients: comparison of FK 506 and cyclosporine immunosuppression. |
1991 |
Transplant. Proc. |
pmid:1721353
|
Paul AA et al. |
CMV retinitis and the use of FK 506. |
1991 |
Transplant. Proc. |
pmid:1721354
|
Reyes J et al. |
Posttransplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression. |
1991 |
Transplant. Proc. |
pmid:1721355
|
de Paulis A et al. |
Characterization of the anti-inflammatory effect of FK-506 on human mast cells. |
1991 |
J. Immunol. |
pmid:1721644
|
Shapiro R et al. |
Kidney transplantation under FK 506 immunosuppression. |
1991 |
Transplant. Proc. |
pmid:1703352
|
Tzakis AG et al. |
Use of FK 506 in pediatric patients. |
1991 |
Transplant. Proc. |
pmid:1703353
|
Jain AB et al. |
Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. |
1991 |
Transplant. Proc. |
pmid:1703354
|
Venkataramanan R et al. |
Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine. |
1991 |
Transplant. Proc. |
pmid:1703355
|
McCauley J et al. |
Changes in renal function after liver transplantation under FK 506. |
1991 |
Transplant. Proc. |
pmid:1721385
|
Tauxe WN et al. |
A comparison of the renal effects (ERPF, GFR, and FF) of FK 506 and cyclosporine in patients with liver transplantation. |
1991 |
Transplant. Proc. |
pmid:1721386
|
McCauley J et al. |
Renal function after conversion from cyclosporine to FK 506 in liver transplant patients. |
1991 |
Transplant. Proc. |
pmid:1721387
|
Hossein-Nia M et al. |
Urinary proteins as a marker of drug-induced renal damage following treatment with cyclosporine or FK 506. |
1991 |
Transplant. Proc. |
pmid:1721388
|
Yamashita T et al. |
Prolongation of pancreaticoduodenal allograft survival in rats by treatment with FK 506. |
1991 |
Transplant. Proc. |
pmid:1721414
|
Fukuzaki T et al. |
Induction of tolerance to islet allografts with preoperative donor spleen cell injection and a short course of FK 506 treatment. |
1991 |
Transplant. Proc. |
pmid:1721415
|
Tzakis AG et al. |
FK 506 rescue in chronic graft-versus-host-disease after bone marrow transplantation. |
1991 |
Transplant. Proc. |
pmid:1721416
|
Masaoka T et al. |
Phase II study of FK 506 for allogeneic bone marrow transplantation. |
1991 |
Transplant. Proc. |
pmid:1721417
|
Markus PM et al. |
The effect of cyclosporine, rapamycin and FK 506 the survival following allogeneic bone marrow transplantation. |
1991 |
Transplant. Proc. |
pmid:1721418
|
Lin CS et al. |
FK-506 and cyclosporin A inhibit highly similar signal transduction pathways in human T lymphocytes. |
1991 |
Cell. Immunol. |
pmid:1707760
|
Vincent SH et al. |
Effects of the immunosuppressant FK-506 and its analog FK-520 on hepatic and renal cytochrome P450 mixed-function oxidase. |
1991 |
Biochem. Pharmacol. |
pmid:1708254
|
Kitahara S et al. |
Lymphoproliferative disorders after FK 506. |
1991 |
Lancet |
pmid:1708846
|
Holechek MJ |
Medication review: FK 506. |
1991 |
ANNA J |
pmid:1708982
|
Michnick SW et al. |
Solution structure of FKBP, a rotamase enzyme and receptor for FK506 and rapamycin. |
1991 |
Science |
pmid:1709301
|
Fabrega AJ et al. |
FK 506 enhances the beneficial effects of donor-specific blood transfusion on allograft survival in rats. |
1991 |
Transplant. Proc. |
pmid:1721447
|
Davies CB et al. |
Effects of donor-specific transfusion, cyclosporine A and FK 506 on rat cardiac allograft survival. |
1991 |
Transplant. Proc. |
pmid:1721448
|
Abu-Elmagd K et al. |
FK 506: a new therapeutic agent for severe recalcitrant psoriasis. |
1991 |
Transplant. Proc. |
pmid:1721449
|
Nikolaidis NL et al. |
Metabolic effects of FK 506 in patients with severe psoriasis: short-term follow-up of seven cases. |
1991 |
Transplant. Proc. |
pmid:1721450
|
Armitage JM et al. |
Preliminary experience with FK506 in thoracic transplantation. |
1991 |
Transplantation |
pmid:1713363
|
Lorber MI et al. |
A comparison of in vivo responses to cyclosporine, FK506, and rapamycin following allogeneic immune challenge. |
1991 |
Transplantation |
pmid:1713364
|
Abu-Elmagd K et al. |
The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. |
1991 |
Transplantation |
pmid:1713365
|
Takada K et al. |
Pharmacokinetics of FK-506, a novel immunosuppressant, after intravenous and oral administrations to rats. |
1991 |
J. Pharmacobio-dyn. |
pmid:1713626
|
Nielsen JB et al. |
Biosynthesis of the immunosuppressant immunomycin: the enzymology of pipecolate incorporation. |
1991 |
Biochemistry |
pmid:2043618
|
Ochiai T et al. |
[Immunosuppressive agents--advances of the developmental studies and the mode of action]. |
1991 |
Nippon Rinsho |
pmid:1715926
|
Jiang H et al. |
Effect of FK-506 on heart allograft survival in the highly sensitized recipient rats as compared with ciclosporin and 15-deoxyspergualin. |
1991 |
Eur Surg Res |
pmid:1723683
|
Fung JJ et al. |
Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. |
1991 |
Transplant. Proc. |
pmid:1703682
|
Stötter H and Lotze MT |
Human lymphokine-activated killer cell activity. Role of IL-2, IL-4, and IL-7. |
1991 |
Arch Surg |
pmid:1726819
|
Karlsson H and Nässberger L |
FK506 lacks the ability to inhibit expression of interleukin-2 receptor beta-chain on human lymphocytes. |
1991 |
J Clin Lab Immunol |
pmid:1726895
|